Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015

Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs

(2018) Mugdha Gokhale et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2018) Melanie J. Davies et al.   DIABETES CARE

Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients

(2017) Fei Wang et al.   MEDICINE

Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013

(2016) Kasia J. Lipska et al.   DIABETES CARE

Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin

(2016) Emilie Bahne et al.   DIABETES OBESITY & METABOLISM

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes

(2016) Suetonia C. Palmer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals

(2016) Nicole B. Gabler et al.   Trials

Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus

(2015) Shuo-Ming Ou et al.   ANNALS OF INTERNAL MEDICINE

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)

(2015) Nikolaus Marx et al.   Diabetes & Vascular Disease Research

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

(2015) Jennifer B. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study

(2015) Jong-Mi Seong et al.   PLoS One

Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants

(2014) Shiying Wu et al.   Cardiovascular Therapeutics

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Adjusting for Instrumental Variables on Bias and Precision of Effect Estimates

(2011) Jessica A. Myers et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration

(2011) Amanda R. Patrick et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

(2010) C. Lamanna et al.   DIABETES OBESITY & METABOLISM

Dealing with heterogeneity of treatment effects: is the literature up to the challenge?

(2009) Nicole B Gabler et al.   Trials

Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies

(2008) A. D. Rao et al.   DIABETES CARE